03-05-2023 : 769 Pharmacists work as Medical Representative, of which 39 work as Senior Medical Representative * 02-06-2020 : 216 non Pharmacists work as Medical Representative, and 54 work as Senior Medical Representative * 05-06-2023 : In Lebanon, 88 generic medicinal products are more expensive than their Originators * 31-12-2019 : A medicinal product refused in Europe is marketed in Lebanon * 05-06-2023 : At least 332 medicinal products are available on the Lebanese market and are not available in the country of origin * 05-06-2023 : The price of the most expensive medicine available in Lebanon is 30434557 LL * 05-06-2023 : At least 1309 medicinal products are more expensive in Lebanon than in the countries of origin * 01-01-2019 : Daktavira, a generic of Daklinza, is registered in Lebanon but has no public price * 31-12-2019 : 352 medicinal products have been declared as non-marketed or withdrawn * 09-11-2021 : 64.72% of lebanese pharmacists are female * 31-12-2019 : 486 medicines were submitted to the Ministry of Health for a marketing authorization, and 514 medicines were registered to date * 15-06-2018 : The Minister of Public Health, has decided to suspend the commercialization of AB Slim (Ab Care Medical Herbs), which contains sibutramine, sildenafil and phenolphthalein * 01-06-2020 : Some Non-Marketed medicines are still imported * 01-06-2020 : Ixempra, a medicinal product withdrawn in Europe is imported to lebanon * 01-06-2020 : A vaccine made in India, removed from WHO list of prequalified vaccines, is submitted for registration in Lebanon * 01-06-2020 : Lebanon has 14 CROs, and is ranked as one of the largest countries in the world in clinical studies. According to the WHO, 817 clinical studies are currently conducted in Lebanon. * 05-01-2021 : * 01-10-2023 : Adakveo is now withdrawn from use in the European Union due to lack of therapeutic efficacy *
Crusia 4000IU* : | |
Type | Medicine Non Marketed |
Originator | Lovenox 4000IU |
Agent | Hikma-Liban |
Distributor | Hikma-Liban |
Laboratory | Rovi |
Manufacturer | Rovi Contract Manufacturing S.L.C. |
Manufacturing Type | G |
Origin | Spain |
ATC | B01AB05 |
Crusia 4000IU* :
Crusia 4000IU* :
Crusia 4000IU* :
Crusia 4000IU* :
Crusia 4000IU* :
Frequency | Percentage |
---|---|
Very Common | ≥ 1/10 |
Common | ≥ 1/100 - < 1/10 |
Uncommon | ≥ 1/1,000 - < 1/100 |
Rare | ≥ 1/10,000 - < 1/1,000 |
Very Rare | < 1/10,000 |
Unknown | Cannot be Estimated |
Effect | Frequency |
---|---|
Allergic reaction | Common |
Alopecia | Not known |
Anaphylactic reactions | Rare |
Anaphylactic shock | Not known |
Anaphylactoid reactions | Rare |
Cephalea | Not known |
Cholestatic liver injury | Not known |
Dermatitis bullous | Uncommon |
Ecchymosis | Very Common |
Epistaxis (Nasal bleeding) | Very Common |
Erythema | Common |
Gastrointestinal bleeding | Very Common |
Haematoma | Very Common |
Haematuria (Hematuria) | Very Common |
Haemorrhage | Very Common |
Haemorrhage intracranial | Uncommon |
Haemorrhagic anaemia | Not known |
Heparin-induced thrombocytopenia | Not known |
Hepatic enzyme increased | Very Common |
Hepatocellular injury | Not known |
Hypereosinophilia | Not known |
Hyperkalaemia | Rare |
Injection site allergic reaction | Common |
Injection site haematoma | Common |
Injection site haemorrhage | Common |
Injection site inflammation | Common |
Injection site irritation | Uncommon |
Injection site necrosis | Uncommon |
Injection site nodule | Common |
Injection site oedema | Common |
Injection site pain | Common |
Intraspinal haematoma | Not known |
Osteoporosis | Not known |
Platelet count increased | Not known |
Post procedural haematoma | Very Common |
Pruritus | Common |
Retroperitoneal haemorrhage | Rare |
Serum transaminase increased | Very Common |
Skin necrosis | Not known |
Thrombocytopenia (Thrombopenia) | Common |
Thrombocytosis | Very Common |
Urticaria | Common |
Vasculitides | Not known |
Crusia 4000IU* :
NB : Products With Same Indication |
Different Units By MoH Code
Crusia 4000IU* MoH 10384 :
Form | Solution for injection |
Packaging | Pre-filled Syringe |
Package Size | 2x0.4ml |
Strength | 40mg = 4000IU Anti-Xa/0.4ml |
NSSF | ✘ |
Quarantine | ✘ |
Reg. Number | 145019/1 |
Submission date | 03/10/2019 |
Registration Year | 03/10/2019 |
Archived Date | 03/05/2023 |
Price Comparison
● Country: | UK | |
● Package Size: | 10 | |
● Public Price: | 22.7 GBP | ( 2,579,832.30 LBP ) |
● Pack size unit used: | 40000 | |
● Cost/Unit: | 0,0006 GBP | ( 0.00 LBP ) |
● Reference: | DMD | |
● Pricing Date: | 08/03/2021 | |
● Type: | Medicine Authorised |
● Country: | France | |
● Package Size: | 2x0.4ml | |
● Public Price: | 9.29 EUR | ( 899,978.04 LBP ) |
● Pack size unit used: | 8000 | |
● Cost/Unit: | 0,0012 EUR | ( 0.00 LBP ) |
● Reference: | ansm | |
● Pricing Date: | 15/05/2021 | |
● Type: | Medicine Authorised |
● Country: | Spain |
● Package Size: | 2x0.4ml |
● Reference: | Agencia Española de Medicamentos y Productos Sanitarios |
● Pricing Date: | 14/10/2019 |
● Type: | Medicine Authorised |
● Country: | Finland |
● Package Size: | 2x0.4ml |
● Reference: | Kela |
● Pricing Date: | 22/04/2021 |
● Type: | Medicine Non Marketed |
You have to register to view this info
Drop File